USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AVIDBIOTICS CORPORATION
Address:
100 Kimball Way
SOUTH SAN FRANCISCO, CA
Phone:
N/A
URL:
N/A
EIN:
120127828
DUNS:
163439511
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,158,315.00 6
SBIR Phase II $1,073,420.00 1

Award List:

HOST RANGE DIVERSITY OF BACTERIOPHAGE FOR Y. PESTIS

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$494,982.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Yersinia pestis, the bacterium responsible for plague, is a Category A pathogen, a significant biowarfare agent. If weaponized, it can easily gain direct access to the respiratory system to cause rapid death by pneumonic plague. Pneumonic plague has fatality… More

Engineered R-type pyocins as bactericidal agents against E.coli O157:H7

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$635,152.00
Agency:
HHS
Principal Investigator:
Dean M. Scholl
Abstract:
DESCRIPTION (provided by applicant): Our overall Goal is to develop our bactericidal R-type pyocin targeting E.coli O157:H7, as a specific therapeutic against infection and contamination. Enterohemorrhagic E. coli (EHEC) are a group of food- and waterborne pathogens that cause illnesses ranging… More

Non-clinical Development of Bactericidal Proteins Targeting Plague

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,073,420.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In our Phase 1 project we have developed R-type pyocins, targetable bactericidal proteins, that kill the plague bacterium, Yersinia pestis, in vitro and are not sensitive to the mechanisms that bacteria use to resist an tibiotics. Thus, these agents are… More

Create, evaluate and develop pre-clinically an engineered R-type pyocin to specif

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$512,103.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Acinetobacter baumannii (A. baumannii) is a human pathogen responsible for recent increases in nosocomial infections of both military and civilian populations. Further emergence of the pathogen's broad resistance to ava ilable antibiotics has emphasized the need… More

Targeted soluble MICA molecules to recruit innate immunity cells to kill specific

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this proposal is to develop a platform that broadly enables the generation of a new class of anti-viral therapeutics that recruit and activate the innate immunity system to attack specifically h uman cells infected with targeted viral… More

TARGETABLE BACTERICIDAL PROTEINS TO SPECIFICALLY KILL CLOSTRIDIUM DIFFICILE BACTE

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
David W. Martin – 650-873-1115
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this proposal and any subsequent phase II proposal is to develop a unique protein agent to prevent Clostridium difficile associated diseases in those patients at high risk rather than wait to treattheir dangerous and costly infections. We aim… More

DIVERSIFYING MICA TO CREATE TARGETED ADAPTERS TO RECRUIT AND ACTIVATE NK CELLS TO

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$316,078.00
Agency:
HHS
Principal Investigator:
David W. Martin – 650-873-1115
Abstract:
DESCRIPTION (provided by applicant): Monoclonal antibodies targeting tumor associated antigens (TAA's) have since 1997, provided safe and efficacious human cancer therapeutics. More recently, bispecific antibodies or bispecific antibody fragments that promote immunologic synapses between cells… More